- Home
- ALEC vs CVRX Comparison
ALEC vs CVRX Comparison
Compare ALEC & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | CVRX |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.2M | 201.0M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALEC | CVRX |
|---|---|---|
| Price | $1.87 | $5.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $3.33 | ★ $13.17 |
| AVG Volume (30 Days) | ★ 1.2M | 257.5K |
| Earning Date | 02-25-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,048,000.00 | $55,969,000.00 |
| Revenue This Year | N/A | $11.91 |
| Revenue Next Year | N/A | $15.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.26 | ★ 18.44 |
| 52 Week Low | $0.87 | $4.30 |
| 52 Week High | $3.40 | $18.55 |
Technical Indicators
Market Signals| Indicator | ALEC | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 23.14 |
| Support Level | $1.74 | $5.34 |
| Resistance Level | $1.94 | $6.09 |
| Average True Range (ATR) | 0.11 | 0.65 |
| MACD | 0.03 | -0.21 |
| Stochastic Oscillator | 76.26 | 1.43 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.